ArticleJournal of pharmaceutical policy and practice2025
Evaluation of risk factors and outcome of patients with polymyxin-resistant critical pathogens gram-negative bacilli in Hospital Kuala Lumpur.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymyxin-resistant gram-negative bacilli pose a formidable challenge in clinical settings globally and the increasing prevalence of resistance has raised concerns regarding treatment options and patient outcomes. This study aimed to evaluate the risk factors, length of hospital stay and mortality among patients with polymyxin-resistant critical pathogens gram-negative bacilli (PR-CP-GNB) and polymyxin-susceptible (PS-CP-GNB) isolates. Methods: A one-year case-control study was conducted using retrospective data from patients admitted to Kuala Lumpur Hospital with a positive culture of CP-GNB. CP referred to Carbapenem-Resistant Acinetobacter baumannii and Carbapenem-Resistant Enterobacterales. Patients with PR-CP-GNB isolates were classified as cases, while those with PS-CP-GNB isolates served as controls. Mortality outcomes were assessed using Chi-Square and Fisher's exact tests, while the length of hospital stay was evaluated using the Mann-Whitney U test. Simple and multiple logistic regression analyses were performed to identify risk factors for PR-CP-GNB. Results: The median age of the 70 patients was 55.5 (IQR 42.6-64.9), with an equal distribution between males and females. Of 70 patients, 50 (71.4%) were identified as PR-CP-GNB and the remaining were PS-CP-GNB. Additionally, 15 isolates were identified as colonisers (12 PR-CP-GNB and 3 PS-CP-GNB). Among the 55 non-coloniser, 38 (69%) were identified as PR-CP-GNB while 17 (31%) had PS-CP-GNB. No significant difference in all-cause mortality (PR-CP-GNB: 60.5%; PS-CP-GNB: 64.7%, Conclusion: Prior ICU admission significantly increased the risk of PR-CP-GNB isolation. Clinicians should consider a history of ICU admission as a major risk factor when evaluating patients for potential polymyxin-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.